Abstract:Background: WD repeat domain 12 (WDR12) plays a crucial role in the ribosome biogenesis pathway. However, its biological function in colorectal cancer (CRC) remains poorly understood. Therefore, this study aims to investigate the roles of WDR12 in the occurrence and progression of CRC, as well as its underlying mechanisms. Methods: The expression of WDR12 was assessed through The Cancer Genome Atlas (TCGA) and the Human Protein Atlas (HPA) database. Functional experiments including Celigo assay, MTT assay, and Caspase-3/7 assay were conducted to validate the role of WDR12 in the malignant progression of CRC. Additionally, mRNA chip-sequencing and ingenuity pathway analysis (IPA) were performed to identify the molecular mechanism. Results: WDR12 expression was significantly upregulated in CRC tissues compared to normal colorectal tissues. Knockdown of WDR12 reduced proliferation and promoted apoptosis of CRC cell lines in vitro and in vivo experiments. Furthermore, WDR12 expression had a significantly inverse association with diseases and functions, including cancer, cell cycle, DNA replication, recombination, cellular growth, proliferation and repair, as revealed by IPA analysis of mRNA chip-sequencing data. Moreover, the activation of cell cycle checkpoint kinases proteins in the cell cycle checkpoint control signaling pathway was enriched in the WDR12 knockdown CRC cell lines. Additionally, downregulation of rac family small GTPase 1 (RAC1) occurred upon WDR12 knockdown, thereby facilitating the proliferation and anti-apoptosis of CRC cells. Conclusion: Our study demonstrates that the WDR12/RAC1 axis promotes tumor progression in CRC. Therefore, WDR12 may serve as a novel oncogene and a potential target for individualized therapy in CRC. These findings provide an experimental foundation for the clinical development of drugs targeting the WDR12/RAC1 axis.

Oncogenic Retinoic Acid Receptor Γ Knockdown Reverses Multi-Drug Resistance of Human Colorectal Cancer Via Wnt/β-catenin Pathway

Oncogenic Retinoic Acid Receptor Α Promotes Human Colorectal Cancer Growth Through Simultaneously Regulating P21 Transcription and GSK3β/β-catenin Signaling.

Oncogenic activity of retinoic acid receptor γ is exhibited through activation of the Akt/NF-κB and Wnt/β-catenin pathways in cholangiocarcinoma.

Retinoic Acid Receptor α Knockdown Suppresses the Tumorigenicity of Esophageal Carcinoma via Wnt/β-catenin Pathway

Retinoic Acid Receptor Α Facilitates Human Colorectal Cancer Progression Via Akt and MMP2 Signaling.

Knockdown of NDRG1 Promote Epithelial-Mesenchymal Transition of Colorectal Cancer Via NF-κB Signaling.

ANGPTL1 Attenuates Colorectal Cancer Metastasis by Up-Regulating Microrna-138

Data from RARγ Downregulation Contributes to Colorectal Tumorigenesis and Metastasis by Derepressing the Hippo–Yap Pathway

RRS1 Silencing Suppresses Colorectal Cancer Cell Proliferation and Tumorigenesis by Inhibiting G2/M Progression and Angiogenesis

Retinoic Acid Receptor Gamma is Required for Proliferation of Pancreatic Cancer Cells

N-myc Downstream-Regulated Gene 1 Promotes Oxaliplatin-Triggered Apoptosis in Colorectal Cancer Cells Via Enhancing the Ubiquitination of Bcl-2

Rhoa Regulates Resistance to Irinotecan by Regulating Membrane Transporter and Apoptosis Signaling in Colorectal Cancer

Nuclear receptor estrogen-related receptor gamma suppresses colorectal cancer aggressiveness by regulating Wnt/beta-catenin signaling

CAC1 Knockdown Reverses Drug Resistance Through the Downregulation of P-gp and MRP-1 Expression in Colorectal Cancer

Retinoid X Receptor Α Enhances Human Cholangiocarcinoma Growth Through Simultaneous Activation of Wnt/β‐catenin and Nuclear Factor‐κb Pathways

Oncogenic Potential Of Retinoic Acid Receptor-Gamma In Hepatocellular Carcinoma

Supplementary Figures S1-S4 from RARγ Downregulation Contributes to Colorectal Tumorigenesis and Metastasis by Derepressing the Hippo–Yap Pathway

Mir-92B-3p Regulates Cell Cycle and Apoptosis by Targeting CDKN1C, Thereby Affecting the Sensitivity of Colorectal Cancer Cells to Chemotherapeutic Drugs

Targeting p38γ to inhibit human colorectal cancer cell progression.

Targeting CD133 reverses drug-resistance via the AKT/NF-κB/MDR1 pathway in colorectal cancer

WDR12/RAC1 axis promoted proliferation and anti-apoptosis in colorectal cancer cells